Cargando…

SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials

BACKGROUND: Median overall survival (OS) in advanced adrenocortical (ACC) is only 12-15 months. Mitotane and chemotherapy are the backbones of current treatment but prolonged disease stabilization is rare. Cabozantinib (CABO) is an oral multi-kinase inhibitor (MKI) of c-MET, VEGFR2, AXL, and RET. OB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kroiss, Matthias, Goebeler, Maria-Elisabeth, Jimenez, Camilo, Malzahn, Uwe, Fassnacht, Martin, Habra, Mouhammed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Adrenal
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553301/ http://dx.doi.org/10.1210/js.2019-SUN-348

Ejemplares similares

SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma
por: Bedrose, Sara Shokry Daniel, et al.
Publicado: (2020)

SUN-211 Active Steroid Hormone Synthesis Renders Adrenocortical Cells Highly Susceptible to Type II Ferroptosis Induction
por: Weigand, Isabel, et al.
Publicado: (2020)

RF19 | PSUN33 Adrenocortical Carcinoma as a Rare Manifestation of Birt-Hogg-Dubé Syndrome
por: Else, Tobias, et al.
Publicado: (2022)

PSAT010 Severe Cholestatic Jaundice (Stauffer Syndrome) as a Rare Paraneoplastic Manifestation in Adrenocortical Carcinoma
por: Murvelashvili, Natia, et al.
Publicado: (2022)

SUN-350 Sterol-O-Acyl Transferase 1 Protein Expression Alone Is Not Sufficient to Predict Response to Mitotane Treatment in Adrenocortical Carcinoma
por: Weigand, Isabel, et al.
Publicado: (2019)

SAT-354 Characterization of Cell Death Induced by SOAT1 Inhibition in Adrenocortical Carcinoma Cells
por: Weigand, Isabel, et al.
Publicado: (2019)

Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production
por: Habra, Mouhammed Amir, et al.
Publicado: (2021)

SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma
por: Tirosh, Amit, et al.
Publicado: (2019)

SUN-179 Oncocytic Adrenocortical Carcinoma: A Case Report
por: Chan, Jessica, et al.
Publicado: (2020)

SUN-353 Adrenocortical Carcinoma: A Single Institution Experience in Mexico
por: Silva-Serrano, Juanita, et al.
Publicado: (2019)

SUN-384 Aldosterone Secreting Adrenocortical Carcinoma and the Importance of Initial Imaging
por: Mehran, Parisa, et al.
Publicado: (2019)

SUN-180 A Case of Deoxycorticosterone-Producing Malignant Adrenocortical Tumor
por: Cartolano, Natasha Scaranello, et al.
Publicado: (2020)

SUN-388 Immune Checkpoint Inhibitor Nivolumab in Advanced or Recurrent Adrenocortical Carcinoma
por: Akunjee, Munaza, et al.
Publicado: (2019)

SUN-378 Adrenocortical Carcinoma Diagnosed During Evaluation of an Incidentally Discovered Adrenal Mass
por: Fatima, Nishat, et al.
Publicado: (2019)

SUN-352 Estrogen, Progesterone, and Androgen Receptor Expressions Predict the Prognosis for Adrenocortical Carcinoma
por: Oguz, Seda, et al.
Publicado: (2019)

SUN-190 Metastatic Adrenocortical Carcinoma in Remission After a Single Dose of Gemcitabine
por: Go, Muriel Tania L, et al.
Publicado: (2020)

SUN-351 Are We Underestimating The Role Of Systemic Chemotherapy In The Treatment Of Localized And Advanced Adrenocortical Carcinoma?
por: Ferreira, Amanda, et al.
Publicado: (2019)

SUN-169 A Rare Case of Adrenocortical Carcinoma Presenting as Hyperaldosteronism Combined with Cushing’s Syndrome
por: Punni, Emma, et al.
Publicado: (2020)

SUN-216 Investigating the Role of the Liver X Receptor in Potentiating Mitotane Therapy in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2020)

SUN-198 Metastatic Progression of Adrenocortical Carcinoma: Phenotypic Transformation to ACTH-Independent Cushing’s Syndrome
por: Ocampo, Javier, et al.
Publicado: (2020)

Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study
por: Elhassan, Yasir, et al.
Publicado: (2021)

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021)

SUN-379 Transformation of Adrenal Adenoma into Adrenocortical Carcinoma in a Cushing Syndrome Patient after Surgery
por: Barsukova, Yuliya, et al.
Publicado: (2019)

SAT-348 Overexpression of the Notch Intracellular Domain Results in Abnormal Adrenal Development.
por: Reid, Olivia, et al.
Publicado: (2019)

FRI191 Changes In The Incidence And Geographical Distribution Of Adrenocortical Carcinoma: A Retrospective Analysis Of A State Cancer Registry
por: Brondani, Vania B, et al.
Publicado: (2023)

SUN-213 The Role of Filamin A (FLNA) in the Regulation of Insulin-Like Growth Factor System in Adrenocortical Carcinomas
por: Peverelli, Erika, et al.
Publicado: (2020)

SUN-182 Rare Case of Adrenocortical Carcinoma with Tumor Extension into the Inferior Venacava, Right Atrium and Right Ventricle
por: Siddiqi, Asmat Qayoom, et al.
Publicado: (2020)

SUN-401 New Right Adrenal Nodule and Beckwith-Wiedemann Syndromein a Girl with Left Adrenocortical Tumor Resection
por: Alradadi, Rasha, et al.
Publicado: (2019)

SUN-218 Analysis of ATRX and ZNRF3 Expression and Copy Number Variation in a Pediatric and Adult Cohort with Adrenocortical Tumors
por: Brondani, Vânia Balderrama, et al.
Publicado: (2020)

SAT-165 Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma
por: Lacombe, Amanda Meneses Ferreira, et al.
Publicado: (2020)

OR04-6 Comprehensive Profiling of the MELK Inhibitor OTSSP167's Action and Its Effect on Sensitization to Wee1 Inhibitor AZD1775 in a Spectrum of ACC Models
por: Bagby, Stacey, et al.
Publicado: (2022)

SUN-356 The Effects of Selective Serotonin Reuptake Inhibitors on Urinary Free Cortisol in Patients with Carney Complex and Primary Pigmented Nodular Adrenocortical Disease
por: Kamilaris, Crystal, et al.
Publicado: (2019)

Evaluation of the Molecular Pathogenesis of Adrenocortical Tumors by Whole-Genome Sequencing
por: Neininger, Kerstin, et al.
Publicado: (2021)

MON-348 Isolated ACTH Deficiency after Administrating Immune Checkpoint Inhibitors: Report of Three Cases and Review of Literature
por: Edo, Naoki, et al.
Publicado: (2019)

SUN-LB39 ATAC-Seq Reveals Dynamic Changes in Chromatin Accessibility Following PKA Activation in NCI-H295R Adrenocortical Cells
por: LaPensee, Christopher Ryan, et al.
Publicado: (2020)

Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study
por: Kimpel, Otilia, et al.
Publicado: (2021)

SUN-160 Development of Adrenocortical Carcinoma in an Adrenal Nodule After Nine Years of Size Stability on Imaging: A Case for Critical Review of Efficacy of Radiographic Size Criteria
por: Tam, Matthew, et al.
Publicado: (2020)

OR04-5 Circulating Cell-Free DNA-Based Biomarkers For Prognostication and Disease Surveillance in Adrenocortical Carcinoma
por: Altieri, Barbara, et al.
Publicado: (2022)

Clinical and Pathological Features of Metastatic Adrenocortical Carcinoma
por: Guiomar, Joana Reis, et al.
Publicado: (2021)

PSUN13 Transcriptional and epigenetic landscapes of adrenocortical tumors
por: Lerario, Antonio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_de55ntb5a9g98lkoe578dbuvbf